RemSleep Holdings Inc. submits an upgrade request to


Tampa, Fla., June 10, 2022 (GLOBE NEWSWIRE) — RemSleep Holdings Inc (OTC PINK: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to patients with obstructive sleep apnea, announced today that the company had officially applied for OTCQB® status with

The company expects to receive a decision on the application in approximately 3-4 weeks. The company believes that the move to the OTCQB® will provide increased benefits to investors, including higher reporting standards, better access to analyst coverage and news outlets, and more comprehensive compliance requirements. The OTCQB® is considered by the Securities and Exchange Commission (SEC) to be an “established public market” for determining the public market price when registering securities for resale with the SEC. OTC Pink is not considered as such, and for this reason most brokers will not trade or recommend OTC Pink stocks. Because the OTCQB® greatly increases transparency, reporting standards, management certification and compliance requirements, most brokers trade stocks on the OTCQB®. Historically, companies that have achieved the OTCQB® level have experienced increased investor awareness, greater liquidity and better visibility of their common stock.

“Listing on the OTCQB® will help our company provide greater shareholder value by allowing us to achieve greater market visibility, expand our pool of potential potential investors, greater stability share price, as well as increased trading liquidity within the investment community. We look forward to broadening our firm’s exposure to a broader and more diverse demographic of domestic and international investors,” said said Tom Wood, CEO of RemSleep, “obtaining FDA approval for our patented DeltaWave CPAP nasal interface, and our upcoming 510k FDA filing for our second CPAP mask. This is cash flow positive and a profitable business. I couldn’t be more excited about what we have in store for our investors and the tire CPAP industry as a whole. We believe this positions RemSleep as a disruptive force. leader in the CPAP industry for years to come.

For more information, see: OTCQB Eligibility Requirements

About the OTC Markets Group and the OTCQB® Venture Capital Market

OTC Markets Group Inc. operates financial markets for 11,000 US and global securities. We organize these securities into three markets based on the quality and timeliness of information a company provides to investors: the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market. We use the power of technology to make markets more efficient, enabling a wide range of companies to enhance their investor experience – all without the cost, complexity and loss of resources common to a stock exchange listing. .

The OTCQB® Venture Market is for US and international companies in the entrepreneurial and development stage. To be eligible, companies must be current on their reports, have a minimum bid price of $0.01, not be bankrupt, and must undergo an annual management verification and certification process. These standards provide a solid foundation of transparency to improve investors’ information and trading experience.

About RemSleep Holdings Inc.

RemSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to patients with obstructive sleep apnea. Our focus is primarily on designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the RemSleep team has a deep knowledge and understanding of CPAP and patient compliance challenges. We strive diligently to ensure that our products make a difference and improve the condition of people suffering from sleep apnea.

Forward-looking statements

Certain statements contained in this press release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without (limited to, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “have the ‘intent’, ‘plan’ or ‘project’ or the negative of these words or other variations of these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, which may cause the Company’s actual results to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially current expectations include, among others, the Company’s inability to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, as well as e other risks disclosed in the Company’s public disclosure filing with the relevant securities regulatory authorities. Nothing contained in this press release should be construed as any indication of future revenues, results of operations or the Company’s share price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in the forward-looking statements, there may be other factors that cause actual results or events not to be not those anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless the applicable securities so require. legislation.

Contact with Investor Relations:

Preya Narain
[email protected]


Comments are closed.